Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

STAR*D Alcohol: Treatment of Depression Concurrent With Alcohol Abuse

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
New York State Psychiatric Institute
ClinicalTrials.gov Identifier:
NCT00369746
First received: August 24, 2006
Last updated: April 9, 2014
Last verified: December 2011

August 24, 2006
April 9, 2014
September 2006
February 2009   (final data collection date for primary outcome measure)
Quick Inventory of Depression- Self Report 16 [ Time Frame: study exit visit, at Week 12 ] [ Designated as safety issue: No ]

Quick Inventory of Depression- Self Report assesses 16 depressive symptoms experienced in the past week, based on self-rating, measured at study exit visit

Scale range:

Each of the four possible answers to each quiz is given an ascending numerical value from 0 to 3, and the total test score is the sum of the following: The highest number from questions 1-4 The number from question 5 The highest number from questions 6-9 The total of each question from 10-14 The highest number from questions 15-16

Total scoring ranges (0-48):

0-5, No Depression Likely 6-10, Possibly Mildly Depressed 11-15, Moderate Depression 16-20, Severe Depression 21 or Over, Very Severe Depression

  • Quick Inventory of Depression – Clinician 16 (QIDS-C 16)
  • Quick Inventory of Depression- Self Report 16 (QIDS-SR 16)
  • Hamilton Depression Scale 17 (HAM-D 17)
Complete list of historical versions of study NCT00369746 on ClinicalTrials.gov Archive Site
  • Timeline Follow Back (TLFB) Average Drinks Per Drinking Day [ Time Frame: 30 days ] [ Designated as safety issue: No ]
    This variable reports average drinks/drinking day in a pre-defined time frame.
  • Quantitative Substance Use Inventory ((SUI) [ Time Frame: 30 days ] [ Designated as safety issue: No ]

    Quantitative Substance Use Inventory ((SUI) Measure substance use

    Administered at either week 12 or 14: Any Illicit Drug Using in last 30 days

  • Timeline Follow Back (TLFB) Drinking Days Per 30 Days [ Time Frame: 30 days ] [ Designated as safety issue: No ]
    This variable reports drinking days in a pre-defined time frame.
  • Timeline Follow Back (TLFB) Maximum Drinks Per Drinking Day [ Time Frame: 30 days ] [ Designated as safety issue: No ]
    This variable reports maximum drinks per drinking day in a pre-defined time frame.
  • Timeline Follow Back (TLFB)
  • Quantitative Substance Use Inventory ((SUI)
  • Treatment Services Review (TSR)
Not Provided
Not Provided
 
STAR*D Alcohol: Treatment of Depression Concurrent With Alcohol Abuse
Treatment of Depression Concurrent With Alcohol Abuse, an Extension of Alcohol Use Disorder in Patients Treated for Depression

The purpose of this study is to determine if having an alcohol use disorder affects recovery from depression, and also whether recovery from depression in patients who have alcohol use disorders is also accompanied by improvement in the alcohol use disorder.

This is an extension of the multi-site sub-study of the National Institute of Mental Health (NIMH) protocol, Sequenced Treatment Alternatives to Relieve Depression (STAR*D), which utilized the infrastructure of the Depression Trials Network to enroll 4,000 subjects diagnosed with Major Depressive Disorder. These subjects initially received 12 weeks of treatment with the anti-depressant citalopram. The thrust of this study was to test treatment algorithms for those subjects who did not respond adequately to initial monotherapy treatment with citalopram or who were unable to tolerate it. The parent protocol also contained several ancillary studies, including a sub-study of subjects with co-morbid alcohol use disorders, which enrolled 130 subjects. Treatment response data was collected at multiple intervals during the 12 week treatment period on depressed subjects both with and without a co-morbid alcohol use disorder.

Comparison: Treatment outcome measures of subjects diagnosed with Major Depressive Disorder will be compared to treatment outcome measures of subjects diagnosed with Major Depressive Disorder and an Alcohol Use Disorder following the initial 12 week citalopram treatment period. This comparison will show whether having a co-morbid alcohol use disorder affects recovery from depression. In addition, alcohol use data of depressed subjects who demonstrated a positive response to anti-depressant treatment will be compared with alcohol use data of depressed subjects who did not have positive treatment outcomes. This comparison will show whether recovery from depression is associated with improvement in the co-morbid alcohol use disorder.

Observational
Observational Model: Case Control
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

Participants in the Sequenced Treatment Alternatives to Relieve Depression

  • Major Depressive Disorder
  • Alcohol Use Disorder
Drug: citalopram
tablets, 60 mg maximum, daily, 12 weeks
Other Name: Celexa
  • Alcohol and major depression, citalopram
    Patients with alcohol use disorder and major depression, treated with citalopram tablets, 20-60 mg, once daily, for 12 weeks
    Intervention: Drug: citalopram
  • Major Depression, citalopram
    Patients with major depression, treated with citalopram tablets 20-60 mg daily, for 12 weeks
    Intervention: Drug: citalopram
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
674
February 2009
February 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Males and females aged 18- 75 years
  • Meets criteria for Non-psychotic Major Depression
  • Signs informed consent and able to comply with study
  • Hamilton Depression Scale (HAM-D 17) >14
  • Endorses any drinking items on Short Michigan Alcoholism Screening Test

Exclusion Criteria:

  • Pregnant women and women of childbearing potential who are not using a medically accepted means of contraception.
  • Women who are breast feeding
  • Patients with suicidal ideation that require hospitalization
  • Patients with unstable physical disorders
  • Patients with a history of allergy to citalopram or history of non-response to an adequate dose of citalopram in the current episode.
  • Patients meeting criteria for the following diagnoses as a primary condition: Schizophrenia, Schizoaffective Disorder, Bipolar I, II, and Not Otherwise Specified, Anorexia nervosa, Bulimia, Obsessive Compulsive Disorder
  • Patients abusing substances which require detoxification. American Society for Addiction Medicine standards for detoxification will be used (Level III.7). Patients with substance abuse who are in substance abuse treatment will be eligible.
Both
18 Years to 65 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00369746
#5173, R01AA013303
No
New York State Psychiatric Institute
New York State Psychiatric Institute
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Study Director: Patrick J. McGrath, MD New York State Psychiatric Institute
New York State Psychiatric Institute
December 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP